Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYON4413 in relapsed/refractory AML and MDS
NCT06359002Phase 1Active, not recruiting
- Sponsor
- Byondis
- Start
- Jun 2024
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of BYON4413 in acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS), sponsored by Byondis. Primary endpoints: Dose-Limiting Toxicities at 21 days and Composite Complete Remission Rate at 24 months. Started Jun 2024; status: active, not recruiting.
02
Drugs
BYON4413
03
Conditions
acute myeloid leukemia (AML)myelodysplastic neoplasms (MDS)
Beyond the preview
Go deeper on NCT06359002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06359002.